Abstract
Antigen detection provides particularly valuable information for medical diagnoses; however, the current detection methods are less sensitive and accurate than nucleic acid analysis. The combination of CRISPR/Cas12a and aptamers provides a new detection paradigm, but sensitive sensing and stable amplification in antigen detection remain challenging. Here, we present a PCR-free multiple trigger dsDNA tandem-based signal amplification strategy and a de novo designed dual aptamer synergistic sensing strategy. Integration of these two strategies endowed the CRISPR/Cas12a and aptamer-based method with ultra-sensitive, fast, and stable antigen detection. In a demonstration of this method, the limit of detection was at the single virus level (0.17 fM, approximately two copies/μL) in SARS-CoV-2 antigen nucleocapsid protein analysis of saliva or serum samples. The entire procedure required only 20 minutes. Given our system’s simplicity and modular setup, we believe that it could be adapted reasonably easily for general applications in CRISPR/Cas12a-aptamer-based detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Key R&D program of China (2020YFA0907800), the National Natural Science Foundation of China (31922002, 31720103901, 31772242 and 31870040), the 111 Project (B18022), the Fundamental Research Funds for the Central Universities [22221818014], the Youth Innovation Promotion Association CAS (Y202027) to W.W and the Open Project Funding of the State Key Laboratory of Bioreactor Engineering.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our work did not involve patient samples, and what we tested were simulated samples of inactivated viruses added to serum and saliva. The serum is purchased from Sigma-Aldrich Company Ltd. The product number is S7023. The saliva is purchased from Beijing Solarbio Science & Technology co.,ltd. The product number is A7990. The inactivated SARS-CoV-2 was prepared according to our previous study (Yang et al, Protein Cell. 2021, 12, 4.).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript is available from the corresponding authors.
